Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 50 versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 50 versus QDOLO.
FENTANYL-50 vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a synthetic opioid agonist primarily acting on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and respiratory depression. It also interacts with kappa and delta receptors to a lesser extent.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
50 mcg intravenously every 5-10 minutes as needed for breakthrough pain or for induction of anesthesia; for transdermal, 12-100 mcg/hour applied every 72 hours.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Terminal elimination half-life: 3-12 hours (mean 7 hours); context: prolonged with continuous infusion or in elderly, hepatic impairment, or obesity due to accumulation in adipose tissue.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Renal: 75% (primarily as metabolites, <10% unchanged); Fecal: 9%; Biliary: minor contribution.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist